Physician profile
Alanna E Angel
NPI 1124005541
$8,145.20
in general payments reported to CMS, 2019-2025
54 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2020: $1,031 · 2021: $1,415 · 2022: $1,196 · 2023: $1,340 · 2024: $1,194 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,720.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $807.32 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $800.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $760.77 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $705.08 | 2021-2025 | Vraylar, Ubrelvy, Viberzi |
| Lilly USA, LLC | $654.17 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $400.67 | 2019-2025 | |
| Glaxosmithkline, LLC. | $369.94 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $353.83 | 2020-2025 | Rexulti |
| Pfizer INC. | $353.35 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $327.12 | 2019-2025 | Trintellix |
| Abbott Laboratories | $319.89 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Octrode |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.79 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Ibsa Pharma INC. | $184.93 | 2021-2024 | Tirosint, Licart, Tirosint |
| Amgen INC. | $163.23 | 2019-2025 | Repatha, Otezla, Prolia |
| Bausch Health US, LLC | $138.22 | 2021-2023 | Aplenzin, Wellbutrin |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alanna Angel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.